Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 1/20 | 0.87 |
| ▸ | LMNA | P02545 | 2/20 | 0.86 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.86 |
| ▸ | HTT | P42858 | 1/20 | 0.86 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.86 |
| ▸ | FERMT2 | Q96AC1 | 4/20 | 0.77 |
| ▸ | CCR1 | P32246 | 1/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.68 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.68 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.68 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.68 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.68 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.68 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.68 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.68 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.68 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.68 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29695676 | 0.99 | CDK1 (0.85) | CDK1LMNAKDM4EHTTHSD17B10 | |
| SCHEMBL1147619 | 0.98 | CDK1 (0.87) | CDK1LMNAKDM4EHTTHSD17B10 | |
| SCHEMBL1147601 | 0.96 | KDM4E (0.84) | CDK1LMNAKDM4EHTTHSD17B10 | |
| SCHEMBL1147603 | 0.95 | CDK1 (0.80) | CDK1LMNAKDM4EHTTHSD17B10 | |
| SCHEMBL1147382 | 0.95 | CDK1 (0.80) | CDK1LMNAKDM4EHTTHSD17B10 | |
| SCHEMBL1147600 | 0.95 | KDM4E (0.82) | CDK1LMNAKDM4EHTTHSD17B10 | |
| SCHEMBL1147663 | 0.95 | KDM4E (0.82) | CDK1LMNAKDM4EHTTHSD17B10 | |
| SCHEMBL1147669 | 0.94 | CDK1 (0.78) | CDK1LMNAKDM4EHTTHSD17B10 | |
| SCHEMBL1146967 | 0.94 | CDK1 (0.78) | CDK1LMNAKDM4EHTTHSD17B10 | |
| SCHEMBL1147009 | 0.94 | CDK1 (0.81) | CDK1LMNAKDM4EHTTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4594520-A2 | COMPOSITIONS CONTAINING OLIGONUCLEOTIDES WITH THERANOSTIC APPLICATIONS | Sixfold Bioscience Ltd. (GB) | 2025-08-06 | — | — | EP | claimed |
| WO-2024069235-A2 | COMPOSITIONS CONTAINING OLIGONUCLEOTIDES WITH THERANOSTIC APPLICATIONS | Sixfold Bioscience Ltd. (GB) | 2024-04-04 | — | — | WO | claimed |
| US-20060014786-A1 | Opthalmic pharmaceutical compositions and methods for treating ocular inflammation | RAUT RAJEEV | 2006-01-19 | — | — | US | claimed |
| EP-0656353-B1 | Aminochinoline derivates useful in the treatment of malaria | HOFFMANN LA ROCHE (CH) | 1998-06-03 | — | — | EP | claimed |
| EP-0656353-A1 | Aminochinoline derivates useful in the treatment of malaria | F. HOFFMANN-LA ROCHE AG (CH) | 1995-06-07 | — | — | EP | claimed |
| EP-4594520-A2 | COMPOSITIONS CONTAINING OLIGONUCLEOTIDES WITH THERANOSTIC APPLICATIONS | Sixfold Bioscience Ltd. (GB) | 2025-08-06 | — | — | EP | disclosed |
| WO-2024069235-A2 | COMPOSITIONS CONTAINING OLIGONUCLEOTIDES WITH THERANOSTIC APPLICATIONS | Sixfold Bioscience Ltd. (GB) | 2024-04-04 | — | — | WO | disclosed |
| US-20230416786-A1 | USE OF AMINOQUINOLINE COMPOUNDS FOR HIGHER GENE INTEGRATION | CELLECTIS SA (FR) | 2023-12-28 | — | — | US | disclosed |
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | THE SCRIPPS RESEARCH INSTITUTE | 2023-11-02 | — | — | US | disclosed |
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | THE SCRIPPS RESEARCH INSTITUTE | 2023-11-02 | — | — | US | disclosed |
| WO-2021225767-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-11-11 | — | — | WO | disclosed |
| US-9073985-B2 | Methods and products for treating proliferative diseases | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2015-07-07 | — | — | US | disclosed |
| US-7084157-B2 | Ophthalmic pharmaceutical compositions and methods for treating ocular inflammation | RAUT RAJEEV | 2006-08-01 | — | — | US | disclosed |
| US-20060014786-A1 | Opthalmic pharmaceutical compositions and methods for treating ocular inflammation | RAUT RAJEEV | 2006-01-19 | — | — | US | disclosed |
| US-20050124653-A1 | Treatment of dna damage related disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-06-09 | — | — | US | disclosed |
| US-20050032834-A1 | Treatment of DNA damage related disorders | ST. JUDE CHILDREN'S RESEARCH HOSPITAL | 2005-02-10 | — | — | US | disclosed |
| US-20050014785-A1 | Treatment of radiation disorders | PERLEGEN SCIENCES, INC. (US) | 2005-01-20 | — | — | US | disclosed |
| WO-2004050837-A2 | TREATMENT OF DNA DAMAGE RELATED DISORDERS | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2004-06-17 | — | — | WO | disclosed |
| EP-0656353-B1 | Aminochinoline derivates useful in the treatment of malaria | HOFFMANN LA ROCHE (CH) | 1998-06-03 | — | — | EP | disclosed |
| EP-0656353-A1 | Aminochinoline derivates useful in the treatment of malaria | F. HOFFMANN-LA ROCHE AG (CH) | 1995-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014785-A1 | Treatment of radiation disorders | XRCC5, XRCC6, QTRT1 | CDK1 3641/4885LMNA 198/4885KDM4E 595/4885 |
| US-20050124653-A1 | Treatment of dna damage related disorders | ERCC1, ERCC5, ERCC2 | CDK1 2175/4885LMNA 210/4885KDM4E 1059/4885 |
| US-20060014786-A1 | Opthalmic pharmaceutical compositions and methods for treating ocular inflammation | AQP4, IL5, CCL11 | CDK1 2083/4885LMNA 4425/4885KDM4E 2475/4885 |
| US-20050032834-A1 | Treatment of DNA damage related disorders | BRCA1, ERCC4, POLN | CDK1 1031/4885LMNA 100/4885KDM4E 4109/4885 |
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | ACE2, SARS1, ACE | CDK1 2977/4885LMNA 2675/4885KDM4E 4497/4885 |
| US-20230416786-A1 | USE OF AMINOQUINOLINE COMPOUNDS FOR HIGHER GENE INTEGRATION | ERCC4, LIG4, LIG3 | CDK1 2766/4885LMNA 412/4885KDM4E 1405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.